Holen Sie sich die Stockscreener-App
0.3856
1.08%
-0.0042
Vorhandelsmarkt:
.39
0.0044
+1.14%
Schlusskurs vom Vortag:
$0.3898
Offen:
$0.38
24-Stunden-Volumen:
459.17K
Relative Volume:
0.04
Marktkapitalisierung:
$16.11M
Einnahmen:
$20.27M
Nettoeinkommen (Verlust:
$-63.80M
KGV:
-0.2537
EPS:
-1.52
Netto-Cashflow:
$-68.35M
1W Leistung:
-5.93%
1M Leistung:
-12.58%
6M Leistung:
-12.40%
1J Leistung:
-64.95%
1-Tages-Spanne:
$0.3763
$0.39
1-Wochen-Bereich:
$0.3763
$0.4348
52-Wochen-Spanne:
$0.1417
$1.27
Carisma Therapeutics Inc Stock (CARM) Company Profile
Firmenname
Carisma Therapeutics Inc
Sektor
Branche
Telefon
(267) 491-6422
Adresse
3675 MARKET STREET, PHILADELPHIA
Vergleichen Sie CARM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CARM
Carisma Therapeutics Inc
|
0.3856 | 17.13M | 20.27M | -63.80M | -68.35M | -1.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-12-10 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-04-11 | Eingeleitet | BTIG Research | Buy |
| 2023-10-03 | Eingeleitet | CapitalOne | Overweight |
| 2023-07-06 | Eingeleitet | Evercore ISI | Outperform |
| 2023-05-31 | Hochstufung | Jefferies | Hold → Buy |
| 2023-05-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-04-14 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Carisma Therapeutics Inc Aktie (CARM) Neueste Nachrichten
What analysts say about Carisma Therapeutics Inc. stockExceptional return forecasts - jammulinksnews.com
What drives Carisma Therapeutics Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com
Carisma Therapeutics Inc. Stock Analysis and ForecastTremendous return on equity - jammulinksnews.com
Is Carisma Therapeutics Inc. a good long term investmentFree Risk Assessment Services - jammulinksnews.com
Carisma Therapeutics Transfers Listing to Nasdaq Capital Market - TipRanks
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVEE, CARM, HLGN on Behalf of Shareholders - Benzinga
How Carisma Therapeutics Inc. stock performs during market volatility200 Percent Profit Outlook - Newser
What makes Carisma Therapeutics Inc. stock price move sharplyFree Top-Rated Stock Analysis - Newser
Why Carisma Therapeutics Inc. stock attracts strong analyst attentionFree VIP Investment Strategies - Newser
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: TURN, HLGN, CARM, and GNTY - The Malaysian Reserve
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE - The Malaysian Reserve
Carisma Therapeutics Inc. (NASDAQ:CARM) Given Average Recommendation of “Hold” by Brokerages - Defense World
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound - insights.citeline.com
Carisma Therapeutics and OrthoCellix Merge to Advance Regenerative Cell Therapy for Orthopedic Diseases - MSN
After laying off most of its staff, struggling Carisma Therapeutics finds a merger partner - The Business Journals
Carisma Therapeutics, OrthoCellix enter definitive merger agreement - Yahoo Finance
Carisma Therapeutics stock soars after proposed merger with OrthoCellix - Investing.com India
CARISMA Therapeutics Plummets 12%: What Drives a Crash Without News? - AInvest
Carisma Therapeutics' 12% Drop: A Mystery Unveiled Through Order Flow and Peer Dynamics - AInvest
CARISMA Therapeutics Plunges 10.36% Amid Market Volatility - AInvest
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLC - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Stock Position Decreased by Millennium Management LLC - Defense World
Millennium Management LLC Takes Position in Marker Therapeutics, Inc. (NASDAQ:MRKR) - Defense World
Carisma Therapeutics Secures Nasdaq Listing Approval - TipRanks
Is the 250% Carisma Therapeutics Stock (CARM) Surge a Sucker’s Rally? - The Globe and Mail
Dow Rises Over 50 Points; US Inflation Rate Increases In May - Benzinga
Carisma Therapeutics Stock (CARM) Retreats 35% After a Massive Rally - TipRanks
US Stocks Mixed; JM Smucker Shares Plunge After Q4 Results - Benzinga
Pre-market Movers: EVGN, WINT, CARM, UNCY... - RTTNews
Why Casey's General Stores Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Recommendation of “Hold” by Brokerages - Defense World
Carisma Therapeutics Reports Q1 2025 Financial Results - TipRanks
Carisma Therapeutics Inc (CARM): An Important Analyst Insights - Stocksregister
Layoff Tracker: Eikon Cuts Workforce by 15%, Citing ‘External Forces’ - BioSpace
Finanzdaten der Carisma Therapeutics Inc-Aktie (CARM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):